Seagen (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Seagen" in English language version.

refsWebsite

Global rank English rank

41archive.today

14^th place

14^th place

low place

low place

5web.archive.org

1^st place

1^st place

49^th place

47^th place

3genengnews.com

low place

6,625^th place

3seattletimes.com

519^th place

316^th place

572^nd place

436^th place

1,684^th place

1,350^th place

4^th place

4^th place

low place

low place

low place

low place

1lifescienceleader.com

low place

low place

1seekingalpha.com

5,344^th place

3,420^th place

2^nd place

2^nd place

1aacrjournals.org

8,869^th place

8,487^th place

1dailyherald.com

3,376^th place

1,867^th place

low place

low place

1bizjournals.com

407^th place

241^st place

1businesswire.com

615^th place

407^th place

79^th place

65^th place

6,452^nd place

3,557^th place

low place

low place

aacrjournals.org

cancerres.aacrjournals.org

Abstract 2436: AGS-16M8F is a novel antibody drug conjugate (ADC) for treating renal and liver cancers; Gudas JM, Torgov M, An Z, Jia XC, Morrison KJ, Morrison RK, Yang P, et al. Cancer Res April 15, 2010 70; 2436. Last Accessed: February 15, 2011

adcreview.com

brentuximab vedotin (SGN35), ADC Review/Journal of Antibody-drug Conjugates
Brentuximab vedotin (ADCETRIS®) Clinical Trials, ADC Review/Journal of Antibody-drug Conjugates
Phase I Trial of SGN-LIV1A Initiated in LIV-1-positive metastatic breast cancer ADC Review / Journal of Antibody-drug Conjugates. October 22, 2013. Last accessed October 23, 2013
Supplemental BLA for Brentuximab Vedotin in Post-Transplant Hodgkin Lymphoma Patients at High Risk of Relapse ADC Review / Journal of Antibody-drug Conjugates, Last accessed February 19, 2015
Enfortumab Vedotin (ASG-22ME, Formerly AGS-22M6E) Clinical trials ADC Review / Journal of Antibody-drug Conjugates; Last accessed February 18, 2015

archive.today

Seattle Genetics Initiates Pivotal Trial of SGN-35 for Hodgkin Lymphoma – Corporate Press Release
Seattle Genetics Initiates Phase II Trial of SGN-35 for Anaplastic Large Cell Lymphoma – Corporate Press Release
Seattle Genetics Initiates Brentuximab Vedotin (SGN-35) Retreatment Clinical Trial – Corporate Press Release
Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration with MedImmune – Corporate Press Release
Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration With Bayer Schering Pharma – Corporate Press Release
Seattle Genetics Announces Discontinuation of Dacetuzumab Phase IIb Diffuse Large B-Cell Lymphoma Clinical Trial – Corporate Press Release
Seattle Genetics Initiates Phase I Clinical Trial of Antibody-Drug Conjugate SGN-75 – Corporate Press Release
Seattle Genetics Announces Termination of Collaboration Agreement with Genentech for Dacetuzumab (SGN-40) – Corporate Press Release
Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with GlaxoSmithKline – Corporate Press Release
Seattle Genetics and Millennium Announce Initiation of Phase I Combination Clinical Trial of Brentuximab Vedotin (SGN-35) for Front-line Hodgkin Lymphoma – Corporate Press Release
Seattle Genetics Achieves Milestone under Antibody-Drug Conjugate Collaboration with Genentech – Corporate Press Release
Seattle Genetics, Takeda and Millennium Announce Initiation of Phase III AETHERA Trial of Brentuximab Vedotin (SGN-35) for Post-Transplant Hodgkin Lymphoma – Corporate Press Release
Seattle Genetics to Receive $9.5 Million Payment from Genentech to Extend Antibody-Drug Conjugate Collaboration – Corporate Press Release
Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Initiation of Phase I Clinical Trial of ASG-5ME for Pancreatic Cancer – Corporate Press Release
Seattle Genetics Expands Antibody-Drug Conjugate Collaboration with Genentech – Corporate Press Release
Seattle Genetics Achieves Milestone under Antibody-Drug Conjugate Collaboration with Agensys, an Affiliate of Astellas – Corporate Press Release
Genmab and Seattle Genetics Enter Into Antibody-Drug Conjugate Research Collaboration – Corporate Press Release
Agensys, an Affiliate of Astellas, and Seattle Genetics Announce Initiation of Phase I Clinical Trial of ASG-5ME for Prostate Cancer – Corporate Press Release
Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with Pfizer – Corporate Press Release
Seattle Genetics and Millennium Announce Initiation of a Phase I Clinical Trial of Brentuximab Vedotin in Combination with Chemotherapy for Front-line Systemic ALCL – Corporate Press Release
Seattle Genetics and Millennium Expand Antibody-Drug Conjugate Collaboration – Corporate Press Release
Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with Abbott – Corporate Press Release
Genmab and Seattle Genetics Expand Antibody-Drug Conjugate Collaboration – Corporate Press Release
Seattle Genetics Announces FDA Accelerated Approval of ADCETRIS(TM) (Brentuximab Vedotin) for Two Indications – Corporate Press Release
Seattle Genetics Announces Initiation of a Phase II Clinical Trial of ADCETRIS(TM) in CD30-Positive Non-Hodgkin Lymphoma – Corporate Press Release
Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer – Corporate Press Release
Seattle Genetics Announces Initiation of a Phase II Clinical Trial of ADCETRIS(TM) in CD30-Positive Non-Lymphoma Malignancies – Corporate Press Release
Millennium and Seattle Genetics Initiate Global Phase 3 Trial of ADCETRIS™ in Patients with CD30-Expressing Relapsed Cutaneous T-cell Lymphoma – Corporate Press Release
Seattle Genetics Announces Initiation of a Phase Ib Trial of SGN-75 in Combination with Everolimus for Patients with Renal Cell Carcinoma – Corporate Press Release
Seattle Genetics Achieves Milestones as Genentech Advances Two Antibody-Drug Conjugates (ADCs) into Phase II Development – Corporate Press Release
Seattle Genetics Announces Initiation of Phase II Trial of ADCETRIS® as Front-line Therapy for Hodgkin Lymphoma Patients Age 60 and Over – Corporate Press Release
Seattle Genetics Expands Antibody-Drug Conjugate Collaboration with Abbott – Corporate Press Release
Millennium and Seattle Genetics Initiate Global Phase 3 Clinical Trial of ADCETRIS® in Previously Untreated Advanced Hodgkin Lymphoma – Corporate Press Release
Seattle Genetics Receives FDA Orphan Drug Designation for ADCETRIS® (Brentuximab Vedotin) in Mycosis Fungoides – Corporate Press Release
Health Canada Approves ADCETRIS® (Brentuximab Vedotin) for the Treatment of Relapsed or Refractory Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL) – Corporate Press Release
Seattle Genetics Initiates Two Phase I Trials of SGN-CD19A – Corporate Press Release
Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with Bayer – Corporate Press Release
Seattle Genetics Initiates Phase 1 Trial of SGN-CD33A in Acute Myeloid Leukemia (AML) – Corporate Press Release
Seattle Genetics Announces Initiation of Phase 2 Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Current Standard of Care for Frontline Diffuse Large B-Cell Lymphoma (DLBCL) – Corporate Press Release
Seattle Genetics Initiates Phase 1 Trial of ADC Candidate, SGN-LIV1A, for Patients with LIV-1-Positive Metastatic Breast Cancer – Corporate Press Release
IMGT/mAb-DB SGN-75 Poiron, C. et al., JOBIM 2010, Paper 13 (2010).

ascopubs.org

jco.ascopubs.org

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study JCO June 20, 2012 vol. 30 no. 18 2190-2196

astellas.us

Agensys and Seattle Genetics Announce Interim Phase I Data from ASG-5ME Clinical Trial for Prostate Cancer Astellas Press Release

bizjournals.com

"Seattle Genetics' ambitious plan for 12 more drugs, 100 more employees - Puget Sound Business Journal". Archived from the original on 29 March 2016.

businesswire.com

"Seattle Genetics, Inc. Announces Corporate Name Change to Seagen Inc". BusinessWire. 8 October 2020. Retrieved 20 January 2023.

cancer.gov

B-cell lymphoma NCI Dictionary of Cancer Terms; Last Accessed February 18, 2015
Anti-Nectin-4 monoclonal antibody-drug conjugate AGS-22M6E National Cancer Institute (NCI) Drug Dictionary

dailyherald.com

"Suicide points to wave of insider trading in health industry". 18 November 2012.

doi.org

Annunziata, CM; Kohn, EC; LoRusso, P; Houston, ND; Coleman, RL; Buzoianu, M; Robbie, G; Lechleider, R (2013). "Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors". Invest New Drugs. 31 (1): 77–84. doi:10.1007/s10637-012-9801-2. PMC 3553417. PMID 22370972.

genengnews.com

"Seattle Genetics to Acquire Cascadian Therapeutics for $614M". 31 January 2018.
"Seattle Genetics, Unum Partner on Cancer Immunotherapies in Up-to-$645M Deal - GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business - GEN". 8 June 2015.
Philippidis, Alex (26 September 2016). "Top 25 Biotech Companies of 2016". Genetic Engineering & Biotechnology News. Mary Ann Liebert. Retrieved 23 December 2019.

heraldnet.com

Goldstein-Street, Jake (4 March 2024). "Pfizer backs out of Everett manufacturing plant after $43B Seagen deal". The Everett Herald. Retrieved 12 March 2024.

lifescienceleader.com

Wright, Rob (13 February 2018). "Seattle Genetics Legacy Of Partnering". Life Science Leader. Retrieved 22 February 2018.

nih.gov

ncbi.nlm.nih.gov

Annunziata, CM; Kohn, EC; LoRusso, P; Houston, ND; Coleman, RL; Buzoianu, M; Robbie, G; Lechleider, R (2013). "Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors". Invest New Drugs. 31 (1): 77–84. doi:10.1007/s10637-012-9801-2. PMC 3553417. PMID 22370972.

pubmed.ncbi.nlm.nih.gov

Annunziata, CM; Kohn, EC; LoRusso, P; Houston, ND; Coleman, RL; Buzoianu, M; Robbie, G; Lechleider, R (2013). "Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors". Invest New Drugs. 31 (1): 77–84. doi:10.1007/s10637-012-9801-2. PMC 3553417. PMID 22370972.

reuters.com

Mishra, Manas (13 March 2022). "Pfizer signs $43 bln Seagen deal in cancer drug push". Reuters.
Seattle Genetics Corporate Profile Reuters
Seattle Genetics, Takeda's cancer drug meets main goal in trial Reuters
"Merck in advanced talks to buy Seagen in nearly $40-bln deal - WSJ". Reuters. 6 July 2022. Retrieved 31 July 2022.

seagen.com

investor.seagen.com

"Seagen Names David R. Epstein as Chief Executive Officer and Director". investor.seagen.com. Archived from the original on 21 November 2022. Retrieved 21 November 2022.

seattletimes.com

"Seattle Genetics aims to put drug on the front line of battling cancer". The Seattle Times. 17 December 2016. Retrieved 10 January 2018.
Lure of riches leads to suicide in Seattle Genetics stock case | The Seattle Times
Geraldo, Renata (5 March 2024). "Pfizer pulls plug on mammoth Seagen pharma factory in Everett". The Seattle Times. Retrieved 12 March 2024.

sec.gov

"Seagen Inc. 2022 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. 15 February 2023.
"Seagen Inc. 2023 Proxy Statement". U.S. Securities and Exchange Commission. 20 March 2022.

seekingalpha.com

Transcripts, SA (10 February 2017). "Seattle Genetics (SGEN) Q4 2016 Results - Earnings Call Transcript". Seeking Alpha. Retrieved 10 January 2018.

thewfund.com

"Team - Perry Fell - W Fund".

web.archive.org

Reuters
"Seagen Names David R. Epstein as Chief Executive Officer and Director". investor.seagen.com. Archived from the original on 21 November 2022. Retrieved 21 November 2022.
Seattle Genetics Presents ADCETRIS® (Brentuximab Vedotin) Data in Diffuse Large B-cell Lymphoma at ASH Annual Meeting Reuters
Seattle Genetics and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate Combination of Adcetris® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Hematologic Malignancies Reuters
"Seattle Genetics' ambitious plan for 12 more drugs, 100 more employees - Puget Sound Business Journal". Archived from the original on 29 March 2016.

wsj.com

"Merck Deal for Seagen Seen as Unlikely by Earnings Release". wsj.com. 15 July 2022. Retrieved 31 July 2022.